What's next for the stock? We take a look at earnings estimates for some clues. Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares are down ...

Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares are down sharply year to date due to unimpressive financial results -- and some of the ...

[Image courtesy of Dexcom/Oura] Dexcom (Nasdaq:DXCM) announced today that it entered into a strategic partnership with Oura, maker of leading smart ring technology. The partnership aims to help people ...

DexCom's devices are incredibly valuable to diabetes patients. The company should continue to increase its addressable market. The stock's valuation looks as reasonable as it has in almost three ...

Oura is partnering with medical device maker Dexcom to integrate data from glucose biosensors with the Oura Ring, which tracks sleep, heart rate and activity. Oura also picked up $75 million from ...

In 2025 the Oura Ring will integrate with Dexcom glucose sensors Dexcom data will sit alongside other health points within the Oura app Dexcom is investing $75 million into Oura, now valued at ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

Smart ring maker Oura announced on Tuesday that it has received a $75 million investment from glucose device maker Dexcom. The investment marks Oura’s Series D funding round and brings the ...